Sovicell GmbH

Sovicell GmbH focuses on developing and providing ready-to-use ADME and DMPK test kits for drug discovery, enhancing laboratory efficiency and facilitating rapid testing processes for pharmaceutical and biotech firms. Founded in Leipzig, Germany, Sovicell GmbH specializes in ADME and DMPK solutions. The company has garnered support from investors such as Global Chance Fund and MIG Verwaltungs AG, completing its latest funding round, Series D, in May 2009, raising USD 1. 19 mn.

Sovicell has closed a total of 3 deals, maintaining a current company valuation of USD 4. 51 mn. Sovicell specializes in the development and provision of ready-to-use ADME (Absorption, Distribution, Metabolism, and Excretion) and DMPK (Drug Metabolism and Pharmacokinetics) test kits and services tailored for drug discovery. Their core offerings include Transil 96-well assay kits designed to assess plasma protein binding and membrane permeability, as well as specialized assays for challenging compounds such as lipophilic and tightly bound drugs.

These kits simplify the assay process by requiring only the addition of the test item, with all necessary components provided, thus enabling rapid results within 30 minutes. Sovicell's customers primarily comprise pharmaceutical companies, biotech firms, and research institutions engaged in drug development across North America, Europe, and parts of Asia. The company aims to address the common challenges in drug discovery, such as the need for efficient assay setups and consistent testing conditions, thereby enhancing the overall productivity of laboratories. Sovicell generates revenue through the sales of its Transil assay kits and associated assay development services, which are structured as direct-to-business transactions.

Clients typically purchase these kits based on their specific research needs, with transactions often completed through standard procurement processes. The company offers various specialized assay kits, including those targeting plasma protein binding, which cater to the unique requirements of different drug types. Additionally, Sovicell may engage in contracts for assay development services, providing tailored solutions to clients looking to optimize their drug discovery workflows. The pricing structure is reflective of the specialized nature of their offerings, ensuring that clients receive high-quality, ready-to-use solutions designed to streamline their research and enhance data accuracy.

Sovicell GmbH plans to expand its product line by developing new assay kits aimed at addressing the specific needs of emerging drug compounds. The company is focused on entering new geographical markets, specifically targeting Asia and North America by 2025. The funding raised in May 2009 will be utilized to support these product developments and market expansions, allowing Sovicell to enhance its research capabilities and broaden its customer base.